UPTAKE OF THE RSVPREF VACCINE DURING PREGNANCY: ASSOCIATIONS WITH SOCIOECONOMIC STATUS, PRENATAL CARE UTILIZATION, AND MATERNAL RISK FACTORS
Author(s)
Xiaofan Liu, MPH1, Jonathan Cloughesy, BS1, Tianzhou (. Yu, MPH, MS, PhD2, Maddalena Ferranna, PhD1;
1University of Southern California, Los Angeles, CA, USA, 2Medicus Economics, Brighton, MA, USA
1University of Southern California, Los Angeles, CA, USA, 2Medicus Economics, Brighton, MA, USA
OBJECTIVES: Respiratory syncytial virus (RSV) is a leading cause of infant respiratory illness. In August 2023, the RSV protein-based vaccine (RSVpreF) became the first maternal vaccine approved in the United States to prevent RSV infection in newborns. Our study is to estimate maternal RSVpreF vaccine uptake among commercially insured pregnant individuals and identify key factors associated with uptake during the vaccine’s first U.S. season.
METHODS: We conducted a retrospective study using Optum’s de-identified Clinformatics® Data Mart Database. The study population included women aged 18 to 50 who had a live birth between October 1, 2023, and January 31, 2024. We assessed adherence to CDC-recommended timing windows for maternal RSVpreF vaccine uptake and examined factors associated with vaccination, including sociodemographic characteristics, maternal health risk factors, prenatal care utilization, and uptake of other vaccines. Multivariable logistic regression was used to identify associations between these factors and maternal RSVpreF vaccine uptake.
RESULTS: Among 13,874 pregnant individuals included in the study, only 14.4% received the RSVpreF vaccine. However, RSVpreF vaccine uptake increased steadily over time, from 1.5% in October 2023 to 28.7% in January 2024. Uptake was higher among those who were older, more educated, had higher incomes, and were more engaged in guideline-recommended prenatal care. Prior influenza vaccination before pregnancy, as well as maternal influenza and Tdap vaccination uptake during pregnancy, were strongly associated with RSVpreF vaccine uptake. In contrast, comorbidities and the Severe Maternal Morbidity index were not associated with maternal RSVpreF vaccination. Among the RSVpreF vaccine recipients, 70.3% were vaccinated within the recommended 32-36 week gestational window.
CONCLUSIONS: Maternal RSVpreF vaccine uptake was low during its first on-market season, with significant disparities by sociodemographic factors, uptake of other vaccines, and adherence to recommended prenatal care. Efforts to improve equitable access and education are needed for effective maternal immunization programs.
METHODS: We conducted a retrospective study using Optum’s de-identified Clinformatics® Data Mart Database. The study population included women aged 18 to 50 who had a live birth between October 1, 2023, and January 31, 2024. We assessed adherence to CDC-recommended timing windows for maternal RSVpreF vaccine uptake and examined factors associated with vaccination, including sociodemographic characteristics, maternal health risk factors, prenatal care utilization, and uptake of other vaccines. Multivariable logistic regression was used to identify associations between these factors and maternal RSVpreF vaccine uptake.
RESULTS: Among 13,874 pregnant individuals included in the study, only 14.4% received the RSVpreF vaccine. However, RSVpreF vaccine uptake increased steadily over time, from 1.5% in October 2023 to 28.7% in January 2024. Uptake was higher among those who were older, more educated, had higher incomes, and were more engaged in guideline-recommended prenatal care. Prior influenza vaccination before pregnancy, as well as maternal influenza and Tdap vaccination uptake during pregnancy, were strongly associated with RSVpreF vaccine uptake. In contrast, comorbidities and the Severe Maternal Morbidity index were not associated with maternal RSVpreF vaccination. Among the RSVpreF vaccine recipients, 70.3% were vaccinated within the recommended 32-36 week gestational window.
CONCLUSIONS: Maternal RSVpreF vaccine uptake was low during its first on-market season, with significant disparities by sociodemographic factors, uptake of other vaccines, and adherence to recommended prenatal care. Efforts to improve equitable access and education are needed for effective maternal immunization programs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HSD122
Topic
Health Service Delivery & Process of Care
Disease
SDC: Pediatrics, SDC: Reproductive & Sexual Health, STA: Vaccines